Bicycle Therapeutics plc
NASDAQ:BCYCBiotechnology
Healthcare
$3.11 -1.36%
-$0.06 today
- Market cap
- $217.99M
- Beta
- 1.54
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$3.14
52W Low $3.95High $9.18
Volume 0.57M
Average 0.49M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$249.68M
FY 2025 · Annual
Investing Cash Flow
-$2.35M
FY 2025 · Annual
Financing Cash Flow
-$131,000.00
FY 2025 · Annual
Cash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (66.82M) | (112.72M) | (180.66M) | (169.03M) | (218.96M) |
| Depreciation & Amortization | 1.41M | 3.69M | 6.55M | 7.17M | 6.42M |
| Deferred Income Tax | (1.67M) | (4.98M) | 3.31M | (5.23M) | (850K) |
| Stock-Based Compensation | 12.08M | 26.78M | 32.48M | 38.08M | 39.46M |
| Change in Working Capital | 38.07M | 672K | 76.66M | (33.46M) | (75.75M) |
| Accounts Receivables | 4.54M | (11.35M) | (1.2M) | (11.95M) | 2.89M |
| Inventory | (4.79M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.2M | 2.56M | 8M | 3.1M | (6.87M) |
| Other Working Capital | 37.12M | 9.46M | 69.86M | (24.61M) | (71.77M) |
| Other Non-Cash Items | 2.14M | 442K | 1.04M | (2.26M) | 0 |
| Operating Cash Flow | (14.79M) | (86.11M) | (60.63M) | (164.72M) | (249.68M) |
| Capital Expenditures | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.36M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 5.49K |
| Investing Cash Flow | (2.03M) | (18.99M) | (2.93M) | (1.24M) | (2.35M) |
| Debt Repayment | 15M | 0 | 0 | (31.91M) | 0 |
| Common Stock Issued | 298.54M | 5.7M | 249.35M | 544.13M | 37.09K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.18M | 989K | 682K | 7.53M | (168.09K) |
| Financing Cash Flow | 320.73M | 6.69M | 250.03M | 519.75M | (131K) |
| Effect of Forex Changes | (1.21M) | (1.12M) | 1.35M | (694K) | 804K |
| Net Change in Cash | 302.69M | (99.53M) | 187.82M | 353.1M | (251.35M) |
| Free Cash Flow | (16.82M) | (105.1M) | (63.56M) | (165.96M) | (252.61M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$219.0M
+ D&A$6.4M
+ Stock-Based Comp$39.5M
- Deferred Tax-$850.0K
- Working Capital-$75.8M
+ Other Non-Cash$0
= Operating Cash Flow-$249.7M
- Capex-$2.4M
= Free Cash Flow-$252.6M
Analysis
FY2025 free cash flow is -$252.6M. FCF conversion is 115.4% of net income. Operating cash flow was -$249.7M, with capex of -$2.4M. The largest bridge item is Working Capital at -$75.8M.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 29, 2026 | |
| 8-K | Current report | Oct 29, 2026 | |
| 4/A | 4/A filing | Oct 7, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 6, 2026 |
Does BCYC generate free cash flow?
Bicycle Therapeutics plc (BCYC) generated -$252.61M of free cash flow in fiscal 2025.
How much operating cash flow does BCYC produce?
Operating cash flow was -$249.68M, before capital expenditures of $2.36M.
Continue the stock analysis
Jump to another research area for this company.